mRNA treatments likely will accelerate the trial process because their purview is so limited, compared to other molecule based treatments. So more likely you’l

mRNA treatments likely will accelerate the trial process because their purview is so limited, compared to other molecule based treatments. So more likely you’ll just get over a shorter release cycle and the longer one gets deprecated, relegated to certain style of treatment that mRNA based investment and research will run laps around anyway, further pushing people to evaluate and prioritize mRNA versions. You can try to hold out for an arbitrary threshold of “long term” for your own comfort level. Its accurate that the state wont be helping you. mRNA is like a file for a 3D printer, telling the body what to print for. Other styles of treatments were showing the body the payload. We will definitely learn how often we can get the body to do this, but I wouldn't call it an inferior beta status. Its just as good (or bad) as the longer process for different kinds of treatment. Same efficacy, which allows me personally to not focus on that.